Pyridostigmine Bromide ER (Pyridostigmine Bromide) Patent Expiration, LOE Window & CMS Spending

Pyridostigmine Bromide ER (Pyridostigmine Bromide) by United States Army Office Surgeon General: FDA Orange Book LOE 2038-06-18, 6 AB generics, $9.9M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorUnited States Army Office Surgeon General
FDA Application & PathwayN020414 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2038-06-18
Orange Book Patents (*PED Extensions)9 patents (0 *PED)
Active AB-Rated Generic Competitors6
2024 CMS Total Public Spend$9.9M
2024 Medicare Part D Spend$8.7M
2024 Medicaid Spend$1.2M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel